## Abstract We have identified 2 antigens recognized by several melanoma‐specific cytolytic T lymphocyte clones isolated from a melanoma patient with a clinical history of tumor regression after immunotherapy. Both antigens are presented by HLA‐A2 and encoded by gene __MAGE‐C2__, a cancer‐germline
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
✍ Scribed by Pierre van der Bruggen; Judy Bastin; Thomas Gajewski; Pierre G. Coulie; Pascale Boël; Charles De Smet; Catia Traversari; Alain Townsend; Thierry Boon
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 738 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Treatment of chondrosarcomas is limited to resection because these tumors are unresponsive to standard adjuvant treatments, such as chemotherapy and radiation. We have previously shown that high‐grade chondrosarcomas express unspecified members of the Melanoma Antigen (MAGE) gene family
## Background and objectives: Using peripheral blood mononuclear cells (pbmcs) from a 10-year survivor with established human leukocyte antigen (hla)-a2(+) and mage-3(+) esophageal cancer cell line (kyse-170), we examined the induction of hla-a2-restricted and mage-3-gene-derived peptide (flwgpralv
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one